PT  - JOURNAL ARTICLE
AU  - Jeong, Sanghwa
AU  - Grandio, Eduardo G.
AU  - Navarro, Nicole
AU  - Pinals, Rebecca L.
AU  - Ledesma, Francis
AU  - Yang, Darwin
AU  - Landry, Markita P.
TI  - Extraction of Viral Nucleic Acids with Carbon Nanotubes Increases SARS-CoV-2 RT-qPCR Detection Sensitivity
AID  - 10.1101/2021.01.22.20224675
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.22.20224675
4099  - http://medrxiv.org/content/early/2021/01/26/2021.01.22.20224675.short
4100  - http://medrxiv.org/content/early/2021/01/26/2021.01.22.20224675.full
AB  - The global SARS-CoV-2 coronavirus pandemic has led to a surging demand for rapid and efficient viral infection diagnostic tests, generating a supply shortage in diagnostic test consumables including nucleic acid extraction kits. Here, we develop a modular method for high-yield extraction of viral single-stranded nucleic acids by using ‘capture’ ssDNA sequences attached to carbon nanotubes. Target SARS-CoV-2 viral RNA can be captured by ssDNA-nanotube constructs via hybridization and separated from the liquid phase in a single-tube system with minimal chemical reagents, for downstream quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection. This nanotube-based extraction method enables 100% extraction yield of target SARS-CoV-2 RNA from phosphate buffered saline in comparison to ∼20% extraction yield when instead using a commercial silica-column kit. Notably, carbon nanotubes enable extraction of nucleic acids directly from 50% human saliva, bypassing the need for further biofluid purification and avoiding the use of DNA/RNA extraction kits. Carbon nanotube-based extraction of viral nucleic acids facilitates high-yield and high-sensitivity identification of viral nucleic acids such as the SARS-CoV-2 viral genome with reduced reliance on reagents affected by supply chain obstacles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge support of the IGI LGR ERA and Citris/Banatao Seed Funding. We acknowledge support of a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI) (to M.P.L.), the Simons Foundation (to M.P.L.), a Stanley Fahn PDF Junior Faculty Grant with Award # PF-JFA-1760 (to M.P.L.), a Beckman Foundation Young Investigator Award (to M.P.L.), a CZI investigator award (to M.P.L), a Sloan Foundation Award (to M.P.L.), a Moore Foundation Award (to M.P.L.), a Cisco Research Center grant (to M.P.L), and a DARPA Young Investigator Award (to M.P.L.). M.P.L. is a Chan Zuckerberg Biohub investigator. Work at the Molecular Foundry was supported by the Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. R.L.P., F.L., and D.Y. acknowledge the support of NSF Graduate Research Fellowships (NSF DGE 1752814).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Per 45 CFR 46.102, human subjects research must be research and involve human subjects according to the below definitions. Research means a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Human subject means a living individual about whom an investigator conducting research: 1. Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or 2. Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens. Per 21 CFR 50.3, human subjects research must be a clinical investigation and involve human subjects according to the below definitions: Clinical investigation means any experiment that involves a test article and one or more human subjects and that either is subject to requirements for prior submission to the Food and Drug Administration under section 505(i) or 520(g) of the act, or is not subject to requirements for prior submission to the Food and Drug Administration under these sections of the act, but the results of which are intended to be submitted later to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit. Human subject means an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient. Note that for device studies, this includes an individual on whom or on whose specimen an investigational device is used. Our study makes the use of pooled and de-identified human saliva biospecimens, but do not intervene/interact with the human subjects. As such, according to the above definitions, the UC Berkeley The Committee for Protection of Human Subjects (CPHS) has determined that our study does not require IRB approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author upon request